Loading news...
AVNS gains on strong SNS and PMR growth, M&A and cost actions, but tariff risks and segment headwinds may weigh on near-term performance.
NEW YORK, March 17, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Avanos Medical, Inc. (NYSE: AVNS) on behalf of the company's shareholders. The investigation seeks to determine whether Avanos Medical's directors breached their fiduciary duties in connection with recent corporate actions.
Avanos Medical, Inc. (AVNS) Presents at The Citizens Life Sciences Conference 2026 Transcript
ALPHARETTA, Ga., March 2, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Dave Pacitti, chief executive officer, and Scott Galovan, senior vice president and chief financial officer, will participate in a fireside chat at the 2026 Citizens Life Sciences Conference on Wed.
Avanos Medical (NYSE: AVNS - Get Free Report) and CardioGenics (OTCMKTS:CGNH - Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings. Risk and Volatility Avanos Medical has a beta of
Enters into Agreement with Bradley L. Radoff ALPHARETTA, Ga.
AVNS shares plunge 10% even after a Q4 earnings and revenue beat, as margin pressure and tariff concerns weigh on investors.
Avanos Medical, Inc. (AVNS) Q4 2025 Earnings Call Transcript
Avanos Medical (AVNS) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.43 per share a year ago.
Exceeded full-year revenue and achieved the top end of full-year earnings-per-share guidance Delivered full-year organic growth of 6% in strategic segments Expanded transformation initiatives expected to deliver $15 to $20 million of incremental annualized savings by the end of 2026 ALPHARETTA, Ga., Feb. 24, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported fourth quarter and full-year 2025 results.
ALPHARETTA, Ga., Feb. 16, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the fourth quarter and full year 2025 on Tues.
ALPHARETTA, Ga., Feb. 3, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) announced today that the Centers for Medicare and Medicaid Services (CMS) has released the 2026 Medicare Hospital Outpatient Prospective Payment System (OPPS) and Medicare Ambulatory Surgical Center (ASC) Payment System Final Rule.
AVNS shows solid 3Q25 momentum from SNS and PMR growth, aided by M&A and cost cuts, even as tariffs and FX volatility linger.
Avanos Medical teams up with an imaging partner to pair RFA with mobile imaging, targeting the shift of complex pain procedures to outpatient care.
ALPHARETTA, Ga., Jan. 20, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) and Siemens Healthineers today announced a strategic co-marketing agreement to advance outpatient and interventional pain care through an integrated ecosystem of imaging and radiofrequency ablation (RFA) technologies.
Avanos Medical, Inc. (AVNS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ALPHARETTA, Ga., Jan. 7, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Dave Pacitti, chief executive officer, will present at the 44th Annual J.P.
AVNS, ALG and CLMB have been added to the Zacks Rank #5 (Strong Sell) List on January 6th, 2026.
Avanos Medical (NYSE: AVNS - Get Free Report) and DexCom (NASDAQ: DXCM - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk. Analyst Recommendations This is a summary of recent ratings
Squarepoint Ops LLC purchased a new stake in Avanos Medical, Inc. (NYSE: AVNS) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 93,572 shares of the company's stock, valued at approximately $1,145,000. Squarepoint Ops LLC owned 0.20% of